Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease

Review of the focuSSced RCT (210 patients with early systemic sclerosis) found that, amongst the 136 patients with ILD, tocilizumab demonstrated an improved FVC% preservation than placebo after 48 weeks treatment (-0.1% vs -6.3%).

Source:

Arthritis & Rheumatology